The obesity paradox: body mass index and outcomes in patients with heart failure.
暂无分享,去创建一个
H. Krumholz | S. Rathore | E. Portnay | J. Curtis | Yongfei Wang | I. Jovin | M. Kosiborod | H. Krumholz | S. Sokol | J. Selter | F. Bader | F. Jadbabaie | Seth I. Sokol
[1] O. Febo,et al. Is nutritional intake adequate in chronic heart failure patients? , 2003, Journal of the American College of Cardiology.
[2] Abdissa Negassa,et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.
[3] Andrew J S Coats,et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. , 2003, Journal of cardiac failure.
[4] Abdullah Al Mamun,et al. Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis , 2003, Annals of Internal Medicine.
[5] C. Lavie,et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. , 2002, The American journal of cardiology.
[6] D. Levy,et al. Obesity and the risk of heart failure. , 2003, The New England journal of medicine.
[7] S A Stansfeld,et al. Adrenocortical, Autonomic, and Inflammatory Causes of the Metabolic Syndrome: Nested Case-Control Study , 2002, Circulation.
[8] Tracey McLaughlin,et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. , 2002, Journal of the American College of Cardiology.
[9] S. Anker,et al. The syndrome of cardiac cachexia. , 2002, International journal of cardiology.
[10] V. Froelicher,et al. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. , 2002, Journal of cardiac failure.
[11] G. Schuler,et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.
[12] H. Gurm,et al. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). , 2002, Journal of the American College of Cardiology.
[13] P. Elwood,et al. Height, body mass index, and survival in men with coronary disease: follow up of the diet and reinfarction trial (DART) , 2002, Journal of epidemiology and community health.
[14] N. Weissman,et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? , 2002, Journal of the American College of Cardiology.
[15] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[16] G. Fonarow,et al. The relationship between obesity and mortality in patients with heart failure. , 2001, Journal of the American College of Cardiology.
[17] K. Swedberg,et al. Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.
[18] A Hofman,et al. The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.
[19] Anita Deswal,et al. Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.
[20] S. Anker,et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.
[21] C. Lavie,et al. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. , 2000, Journal of the American College of Cardiology.
[22] S. Yusuf,et al. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. , 2000, Pharmacotherapy.
[23] S. Dunlap,et al. Association of body mass, gender and race with heart failure primarily due to hypertension. , 1999, Journal of the American College of Cardiology.
[24] M. Thun,et al. Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.
[25] P Royston,et al. The use of fractional polynomials to model continuous risk variables in epidemiology. , 1999, International journal of epidemiology.
[26] J. Bower,et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. , 1999, Kidney international.
[27] Marvin A. Konstam,et al. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.
[28] P. Poole‐Wilson,et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.
[29] H. Volk,et al. Systemic inflammation in patients with heart failure. , 1998, European heart journal.
[30] D. Siscovick,et al. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. , 1998, American journal of public health.
[31] P. Ponikowski,et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.
[32] P. Poole‐Wilson,et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.
[33] P. Ponikowski,et al. Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.
[34] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[35] S. Ellis,et al. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. , 1996, The American journal of cardiology.
[36] D. Mann,et al. Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .
[37] D. M. Barr,et al. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. , 1996, Controlled clinical trials.
[38] D. Mann,et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.
[39] O. Febo,et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.
[40] R. Roubenoff,et al. The nutrition implications of cardiac cachexia. , 2009, Nutrition reviews.
[41] D. Mann,et al. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.
[42] G. Morris,et al. Tumour necrosis factor alpha in severe congestive cardiac failure. , 1993, British heart journal.
[43] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.